This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Hedge Fund Favorites to Buy This Fall

Johnson & Johnson

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

You don't get anymore blue-chip than Johnson & Johnson (JNJ). The $189 billion health care firm may be best known for consumer products like Band-Aid brand bandages and Tylenol, but the firm also owns huge medical device and pharmaceutical units too.

Hedge funds picked up shares of JNJ en masse in the second quarter, piling on 18.97 million shares to hike their holdings of the stock up to $4.53 billion. (Johnson & Johnson is one of the top holdings of Renaissance Technologies.)

>>5 Blue-Chip Stocks to Buy to Beat the S&P

Johnson & Johnson is focused on staying a well-diversified healthcare company. While pharma ballooned to nearly 40% of the firm's sales in recent years, that number should make its way down below 30% again in the near-term, thanks to the same patent losses challenging the rest of the industry and major acquisitions in the medical device arena. Healthcare is a recession-resistant business that's only looking stronger in the wake of healthcare reform. Regardless of the politics involved, more folks able to pay for JNJ's drugs and medical devices will ultimately boost the firm's bottom line.

Already, JNJ has mountains of cash. At last count, the firm's coffers stood $17 billion deep, offsetting a debt position of just over half that. That abundance of dry powders should continue to provide growth-by-acquisition opportunities for the firm (even after the huge Synthes deal), and keep its dividend payout big.

Investors looking for a defensive addition to their portfolio could do worse than copying hedge funds on the JNJ trade.

4 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,078.58 -94.10 -0.55%
S&P 500 1,984.08 -10.21 -0.51%
NASDAQ 4,510.43 -17.2590 -0.38%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs